1.
ERJ Open Res
; 7(1)2021 Jan.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33816603
RESUMEN
About half of the patients who initiate therapy with mepolizumab discontinue treatment within the first or second year. Concomitant use of short-acting ß2-agonists and oral corticosteroids drops during mepolizumab use. https://bit.ly/3aRISqS.